Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third

Recent Results in Cancer Research

Volumn 182, Issue , 2010, Pages 65-72

  Lehmann, Kuno ^a   Schneider, Paul M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLOOXYGENASE 2; CYTOKERATIN 20; CYTOKERATIN 7; GLYCOPROTEIN; I KAPPA B KINASE BETA; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; MUCIN 6; MYC PROTEIN; PROTEIN P53; TUBERIN; UVOMORULIN;

CANCER CLASSIFICATION; CARDIA CARCINOMA; CELL CYCLE REGULATION; CELL SURFACE; DIFFERENTIAL DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; LYMPHADENECTOMY; METHYLATION; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; UPPER GASTROINTESTINAL TRACT; ADENOCARCINOMA; APOPTOSIS; CARDIA; CHEMISTRY; ESOPHAGUS TUMOR; GENETICS; PATHOLOGY; STOMACH TUMOR; TUMOR INVASION;

ADENOCARCINOMA; APOPTOSIS; CARDIA; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS;

EID: 77956048696     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-70579-6_5     Document Type: Review

References (65)

1. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV (2004) NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239:491-500
2. Anderson LA, Murphy SJ, Johnston BT, Watson RGP, Ferguson HR, Bamford KB, Ghazy A, McCarron P, McGuigan J, Reynolds JVet al. (2008) Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 57:734-739
3. Arul GS, Moorghen M, Myerscough N, Alderson DA, Spicer RD, Corfield AP (2000) Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study. Gut 47:753-761
4. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA (2002) Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 20:2971-2979
5. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J (1998) Altered cadherin and catenin complexes in the Barrett's esophagus- dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 152:135-144
6. Barclay JY, Morris A, Nwokolo CU (2005) Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 17:221-227
7. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122:1113-1121
8. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645-654
9. Buskens CJ, Sivula A, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ, Ristimaki A (2003) Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 52:1678-1683
10. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122:1800-1807
11. Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, Turhal NS (2007) Vascular endothelial growth factor, hypoxiainducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 72:111-117
12. Chang Y, Gong J, Liu B, Zhang J, Dai F (2004) Gene expression profiling in Barrett's esophagus and cardia intestinal metaplasia: a comparative analysis using cDNA microarray. World J Gastroenterol 10:3194-3196
13. Couvelard A, Cauvin JM, Goldfain D, Rotenberg A, Robaszkiewicz M, Flejou JF (2001) Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut 49:761-766
14. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF (2000) Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 192:14-18
15. Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, Henriquez A (2002) Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 97:554-560
16. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053
17. Dixon MF, Mapstone NP, Neville PM, Moayyedi P, Axon ATR (2002) Bile reflux gastritis and intestinal metaplasia at the cardia. Gut 51:351-355
18. Driessen A, Nafteux P, Lerut T, Van Raemdonck D, De Leyn P, Filez L, Penninckx F, Geboes K, Ectors N (2004) Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications. Mod Pathol 17:49-55
19. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PVet al. (2000) Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60:5021-5026
20. El-Rifai W, Frierson HF Jr, Moskaluk CA, Harper JC, Petroni GR, Bissonette EA, Jones DR, Knuutila S, Powell SM (2001) Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 121: 592-598
21. Fitzgerald RC (2006) Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55:1810-1820
22. Flejou JF, Gratio V, Muzeau F, Hamelin R (1999) p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol Pathol 52:263-268
23. Flucke U, Steinborn E, Dries V, Monig SP, Schneider PM, Thiele J, Holscher AH, Dienes HP, Baldus SE (2003) Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 43:127-134
24. Glickman JN, Shahsafaei A, Odze RD (2003) Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol 27:1357-1365
25. Gulmann C, Lantuejoul S, Grace A, Leader M, Patchett S, Kay E (2005) Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT. Dig Liver Dis 37:439-445
26. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
27. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH, DeMeester TR (2000) Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 231:179-187
28. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi Met al. (2007) Inhibition of cyclooxygenase- 2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67: 10181-10189
29. Kacar F, Meteoglu I, Yasa H, Levi E (2007) Helicobacter pylori-induced changes in the gastric mucosa are associated with mitogen-activated protein kinase (MAPK) activation. Appl Immunohistochem Mol Morphol 15:224-228
30. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 98:1445-1452
31. Kaur BS, Ouatu-Lascar R, Omary MB, Triadafilopoulos G (2000) Bile salts induce or blunt cell proliferation in Barrett's esophagus in an aciddependent fashion. Am J Physiol Gastrointest Liver Physiol 278:G1000-G1009
32. Kim MA, Lee HS, Yang HK, Kim WH (2005) Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer 103: 1439-1446
33. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R (1998) Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115:1381-1386
34. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K (2007) Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14:2738-2747
35. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
36. Liu GS, Gong J, Cheng P, Zhang J, Chang Y, Qiang L (2005) Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia. World J Gastroenterol 11: 6360-6365
37. Marsman WA, Birjmohun RS, van Rees BP, Caspers E, Johan G, Offerhaus A, Bosma PJ, Jan J, van Lanschot B (2004) Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia. Clin Cancer Res 10:8479-8485
38. Mattioli S, Ruffato A, Di Simone MP, Corti B, D'Errico A, Lugaresi ML, Mattioli B, D'Ovidio F (2007) Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors. Ann Thorac Surg 83: 1814-1819
39. Menke-Pluymers MB, van Drunen E, Vissers KJ, Mulder AH, Tilanus HW, Hagemeijer A (1996) Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Cancer Genet Cytogenet 90:109-117
40. Morales CP, Lee EL, Shay JW (1998) In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 83:652-659
41. Morales CP, Souza RF, Spechler SJ (2002) Hallmarks of cancer progression in Barrett's oesophagus. Lancet 360:1587-1589
42. Mueller JD, Stein HJ, Oyang T, Natsugoe S, Feith M, Werner M, Rudiger Siewert J (2000) Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction. Cancer 89:1874-1882
43. Novak A, Dedhar S (1999) Signaling through betacatenin and Lef/Tcf. Cell Mol Life Sci 56:523-537
44. Nurgalieva Z, Lowrey A, El-Serag HB (2007) The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review. Dig Dis Sci 52:1345-1354
45. Ormsby AH, Goldblum JR, Rice TW, Richter JE, Falk GW, Vaezi MF, Gramlich TL (1999) Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 30:288-294
46. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR et al. (1996) Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111:323-331; discussion 331-1323
47. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR (2000) P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6:3153-3158
48. Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR (2006) Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol 94: 307-315
49. Shen B, Ormsby AH, Shen C, Dumot JA, Shao YW, Bevins CL, Gramlich TL (2002) Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer 94:820-831
50. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM (2001) Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase- 1 expression. Cancer Res 61:4879-4884
51. Siewert JR, Feith M, Stein HJ (2005) Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic- anatomic subclassification. J Surg Oncol 90:139-146; discussion 146
52. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457-1459
53. Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9:35-41
54. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M (2007) Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer 96:631-638
55. Taniere P, Borghi-Scoazec G, Saurin JC, Lombard-Bohas C, Boulez J, Berger F, Hainaut P, Scoazec JY (2002) Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol 26:1213-1221
56. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood SE, Jankowski JA (2003) Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52:174-180
57. van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, Rosenberg C (1999) Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31- 32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 59:748-752
58. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ (2005) Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol 58:722-724
59. Von Rahden BH, Stein HJ, Siewert JR (2006) Surgical management of esophagogastric junction tumors. World J Gastroenterol 12:6608-6613
60. Weiss MM, Kuipers EJ, Hermsen MA, van Grieken NC, Offerhaus J, Baak JP, Meuwissen SG, Meijer GA (2003) Barrett's adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications. J Pathol 199:157-165
61. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58:2929-2934
62. Wu J, Xia HHX, Tu SP, Fan DM, Lin MCM, Kung HF, Lam SK, Wong BCY (2003) 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 24:243-247
63. Yanagi M, Keller G, Mueller J, Walch A, Werner M, Stein HJ, Siewert JR, Hofler H (2000) Comparison of loss of heterozygosity and microsatellite instability in adenocarcinomas of the distal esophagus and proximal stomach. Virchows Arch 437:605-610
64. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O (2004) Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96:388-396
65. Yen C-J, Izzo JG, Lee D-F, Guha S, Wei Y, Wu T-T, Chen C-T, Kuo H-P, Hsu J-M, Sun H-Let al. (2008). bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 68:2632-2640